

INDEX

A

Acute coronary syndrome (ACS)255
 Acute kidney injury62
 Acute myocardial infarction (AMI)..... 61, 254
 ACVR1 and TSPAN3.....268, 270
 ACVR1B.....266, 267
 Adenosine triphosphate-binding cassette transporter A1
 (ABCA1)..... 230, 235, 251, 253
 Adipocyte differentiation..... 230, 242–248
 Adipogenesis 228–230, 242–250, 253
 Adiponectin receptor 1 (ADIPOR1)250, 251
 AGO2 3, 29, 44, 59
 AGO-miRNA complexes.....3
 Alzheimer's disease6, 7, 13, 61, 129
 Amyotrophic lateral sclerosis (ALS).....61
 Anaplastic thyroid cancers (ATCs)..... 261, 272–276
 Animal models 45, 228, 231
 Animal/xenografts models.....62
 AntagomiR..... 6, 231, 247
 Antagomirs6, 62, 99, 233, 247
 Anti-miRNA oligonucleotides (AMOs)62
 Anti-miRs62
 Antisense8–10, 13, 14, 47–49, 62, 233, 256, 268
 Anti-sense oligonucleotides..... 13, 99, 252
 ASE left (ASEL).....163
 ASE right (ASER).....163
 ASH1L and MLL1 proteins272
 ATAC-seq165
 Aurora-like kinase 2 (ALK2) 243, 244, 246

B

Bacterial noncoding RNAs
 Batch effect.....187–195
 Beta-cell function59
 Bioinformatics 3, 16, 40, 78, 117, 123,
 165, 174, 208, 252
 Biomarkers5, 11–13, 57, 233, 256, 265
 Blood 5, 57–59, 61, 63, 233, 256, 262, 265
 Bio-Ontology83–90
 BMP8A.....266, 267
 BMPR1A266, 267
 Bone morphogenetic proteins (BMPs).....242
 BRAF(V600E).....265
 Breast cancer.....3–6, 11–13, 58, 127

C

Caenorhabditis elegans.....2, 27, 34, 93, 96,
 114, 135, 136, 153, 161–163, 212, 214, 217, 233
 Cancers/tumors3, 27, 44–45, 58, 126,
 160, 179, 193, 220, 241, 261
 Carbohydrate response element-binding protein
 (ChRE-BP)229–230
 Cardiac hypertrophy 129, 232, 235
 Cardiovascular diseases (CVDs)..... 60, 61, 254–256
 CCAAT-enhancer-binding protein (C/EBP)230,
 243–245
 CCND3 (cyclin D3)45, 266
 ceRNAs8, 15
 ChIP-seq33, 165
 Chronic lymphocytic leukemia (CLL)4, 5, 58
 CircRNA8, 15
 Circulating microRNAs58
 cis-regulatory element (CRE) 160, 161, 166
 c-Jun N-terminal kinase 1 (JNK1).....251, 252
 Clustered regularly interspaced short palindromic repeats
 (CRISPRs)48, 50–51
Cog-1163
 Coronary artery disease (CAD)..... 60, 233, 255
 Crohn's disease61
 Cross-linking immunoprecipitation (CLIP) 47, 97,
 101, 102, 116, 120
 Crosslinking immunoprecipitation and sequencing of
 hybrids (CLASH)102

D

Data mining 73, 116, 117, 187
 Data representation88
 Deadenylation 3, 57, 159
 Decay..... 10, 34, 123, 159
 Dedifferentiated fat (DFAT) cells244, 246
 Degenerated *k*-mer.....185
 Destruction of host microRNAs by viruses47
 Diabetes..... 58–60, 63, 75, 179, 225–226,
 234–235, 241, 254
 Diabetes mellitus60, 225
 Diabetes-related complications226
 Diabetic cardiac complications231–232
 Diabetic cardiomyopathies231, 232
 Diabetic kidney disease..... 61, 62

Diabetic macrovascular complications
 Diabetic nephropathy (DN) 225, 230–231, 236
 Diagnostics 57
 Dicer..... 2, 7, 28–30, 32, 34, 44, 59, 99, 160, 212, 244
 Diffuse large B cell lymphoma (DLBCL)..... 59
 DiGeorge critical region 8 (DGCR8) 29, 59, 212
 Dimension decreasing 179
 DNase-seq..... 165
 DROSHA 2, 28, 29, 34, 159, 211

E

Early growth response (EGR2) 244, 247
 Ectopic pregnancy 58, 61
 EFEMP2 270, 271
 EGF signaling pathway 273
 Embryonic stem cells (ESCs)..... 13, 15, 33, 242, 244
 Enhancer 51, 124, 160–162, 164, 165, 231
 EP300 interacting inhibitor of differentiation 1
 (EID-1) 243, 244
 Ether-a-go-go-related gene 232
 Euglycemic-hyperinsulinemic clamp 228
 Exosomes 2, 5, 13, 58
 Exportin-5 28, 29, 59
 Expression profile 58, 59, 61, 164, 176,
 220, 221, 228, 231, 233, 250, 252, 256, 262, 275, 276
 Extracellular regulated MAP kinase (Erk) 244, 246

F

Factor analysis 184, 185
 Fatty acid binding protein 4 (FABP4)..... 244
 Feed-back loops 163
 Feed-forward loops (FFLs) 125, 126, 163
 FN1 and ITGA2 gene 266
 Follicular thyroid carcinomas (FTCs) 261, 268–272
 Fomivirsen 62
 Free fatty acids 229
 Functional annotations 117, 128, 219, 247
 Functional miRNA-mRNA regulatory modules
 (FMRMs) 219

G

Gapped *k*-mer 182, 183, 185
 Gene *BECN1* 273
 Gene expression 2, 3, 6, 9, 14, 35, 45, 48,
 51, 52, 57, 60, 61, 78, 94, 98, 123, 124, 126, 127, 157,
 159, 161, 163, 164, 179, 190–192, 218, 226, 231, 254,
 261, 262, 266, 272
 Gene identification 214
 Gene regulation 99, 109, 110, 162–164
 Gene regulatory network 13, 159, 162,
 164–166, 208, 218
 Gene targeting 34, 273
 Genome-wide analysis 93–103, 164
 Glioblastoma 4, 58, 59

Glucose homeostasis 226, 229, 234, 235, 252, 253
 Glucose transporter-4 (GLUT4) 229, 251
 Growth factor receptor-bound protein 10 (GRB10) 251

H

Hepatic diseases 62
 Hepatitis C virus (HCV) 40, 44, 47, 60
 Hepatocellular carcinoma (HCC) 33, 44, 58, 252
 Hepatocyte nuclear factor 1beta (HNF1B) 251, 252
 Hepatocyte nuclear factor 4a (HNF4a) 251, 252
 High mobility group AT-hook 2 (HMGA2) 5, 244, 275
 High-density lipoproteins (HDL) 230, 253
 High-dimension 179–185
 High-throughput sequencing of RNA isolated by
 crosslinking immunoprecipitation
 (HITS-CLIP) 47, 101
 Host gene regulation by viral microRNAs
 Host microRNAs regulating viruses 39–46, 49, 50
 Human adipose tissue-derived mesenchymal stem cells
 (hASCs) 244
 Hypertension (HT) 14, 232, 241, 254, 255

I

Illumina 170, 171, 173, 174
 Immunoprecipitation 47, 100–103, 116, 120
 Individual-nucleotide resolution CLIP (iCLIP) 102
 Initiator (Inr) sequences 160
 Insulin receptor substrate-1 (IRS1) 243, 247, 266
 Insulin resistance (IR) 225, 228, 229,
 234, 242, 250–254
 Insulin secretion 226–228, 230, 234, 235
 Insulin sensitivity 228–230, 236, 247, 252, 253
 Insulin-like growth factor-1 (IGF-1) 229, 234,
 251, 252
 Insulin-sensitive glucose transporter-4 (GLUT4) 244
 Ion Torrent 170, 171, 173, 174
 Ipomersen 62

K

Kidney diseases 61
 KIT 3'-UTR 264
 Kmer 179–183
 Kruppel-like 243
 Kruppel-like factor 5 (KLF5) 244, 246
 Kruppel-like transcription factor 15 (KLF15) 229, 234
 K-tuple 179, 181–182
 Kynamro 62

L

Let-7 3–6, 15, 34, 59, 62, 161, 162,
 233, 243, 244, 273, 275
 Let-7 family 34, 59, 275
 Leukemia 4, 5, 41, 58, 59

Lipid metabolism60, 229–230, 246, 247
 Long non-coding RNAs (lncRNAs) 1, 8–16, 27,
 35, 51, 120
 Long QT syndrome.....235
 Lsy-6163
 Lung adenocarcinoma 10, 58

M

Machine learning.....94, 96–98, 111, 115–116,
 124, 135, 136, 141, 149–151, 155, 211–222
 Mechanistic target of rapamycin (mTOR).....4, 251, 252
 Medullary thyroid carcinoma (MTC) 261, 262,
 276–277
 Messenger RNA (mRNA)2, 3, 5, 7, 9, 10, 15,
 27–29, 35, 46, 47, 57, 62, 93, 94, 96, 97, 100–102, 109,
 125, 159, 174, 181, 208, 211, 226, 242, 246, 262, 264,
 272, 276–277
 Messenger RNA degradation3, 10, 31, 102, 262
 Methylation.....9, 31, 32, 165, 193
 Microarray..... 63, 78, 98, 99, 117, 139, 142,
 169, 172, 175, 183, 185, 188, 192, 195, 220, 232, 245,
 250, 253, 265–267, 274, 275
 MicroRNA (miRNA)1–16, 27–35, 39–46, 49,
 50, 57–63, 102, 109–120, 123–130, 134–157, 159–166,
 176, 185, 188, 192–195, 197–209, 222, 225–236,
 241–256, 261–277
 MicroRNA-122.....34
 MicroRNA degradation 32, 34–35, 47, 102
 MicroRNA genomic loci.....28, 160
 MicroRNA processing..... 28, 34, 44, 262
 MicroRNA response to viral infection46
 MicroRNA sequencing.....176
 MicroRNA tailing..... 32, 34
 MicroRNA target databases165
 MicroRNA target prediction 96, 112, 120,
 134, 135, 140, 142–144, 146–148, 150–152, 154, 156,
 215–220, 222
 MicroRNA transcription 2, 3, 5, 28, 29,
 31–33, 35, 57, 123–125, 127, 159–163, 179, 211, 242,
 243, 246, 250, 254, 262, 273
 MicroRNA web resources120
 Microvesicles 2, 58
 miR-1 8, 60–62, 129, 228, 229, 232,
 234, 254, 255, 263, 269
 miR-8243, 246
 miR-96, 7, 164, 227, 234
 miR-10b 59, 62, 270, 272
 miR-14 230, 235, 247
 miR-15a 4, 43, 59, 62, 227, 228, 233, 234
 miR-164, 43, 58, 61, 62, 227, 228, 250, 263, 266
 miR-17-92 cluster..... 4, 5, 7, 59
 miR-17-3p249, 250
 miR-17-5p 7, 249, 250
 miR-17-92..... 245, 275, 276

miR-17-92.....262
 miR-21 2, 4, 5, 8, 45, 46, 59, 228,
 230, 232–234, 245, 262, 265, 274, 276
 miR-22 45, 60, 61, 161, 211, 212, 230
 miR-22*.....61
 miR-23a 60, 61
 miR-24 60, 229, 232–234, 251, 254
 miR-25 59, 274, 275
 miR-26a60, 62, 264, 269, 273–275
 miR-27 35, 47, 164, 245
 miR-27a 60, 61, 245
 miR-27a/27b243
 miR-27b245
 miR-298, 59, 61, 232, 253
 miR-29a7, 60, 61, 228, 231, 235, 251, 253, 266, 267
 miR-29b 7, 62, 228, 233, 253, 265, 274
 miR-29c253
 miR-30 family245
 miR-30a-5p.....59, 248, 249, 265, 274
 miR-30c 119, 129, 248, 249
 miR-31 59, 245, 266, 267
 miR-33a 62, 230, 235, 249, 251, 253
 miR-33a/b.....251, 253
 miR-34 59, 162
 miR-34a 4, 6, 60, 62, 228, 234, 249, 250
 miR-92a 5, 42, 61, 255, 270, 272
 miR-93252
 miR-96 59, 227, 234
 miR-99a 4, 249–252
 miR-10159, 61, 62, 129, 266, 269
 miR-103 59, 246, 248, 249, 251, 253
 miR-106a61
 miR-107 59, 61, 119, 227, 243,
 246, 248, 249, 251, 253
 miR-122 44, 60, 62, 230, 236, 247, 249, 251
 miR-125a 59, 129
 miR-125b 3, 43, 59, 273
 miR-126 59–61, 119, 229, 233, 251, 253, 255
 miR-130 243, 246, 251
 miR-130a-3p.....252
 miR-132 60, 249, 250
 miR-133 15, 35, 62, 129, 229, 232, 235, 254
 miR-133a228, 229, 234, 250, 255
 miR-134 62, 249, 250, 263
 miR-138 42, 233, 244, 245, 266, 267, 273–275
 miR-141 5, 15, 59
 miR-143 62, 230, 232, 235, 245, 248, 251, 253
 miR-14515, 33, 59, 62, 119, 233, 246, 249, 250
 miR-146a5, 7, 8, 61, 228, 233, 255, 263, 272, 275
 miR-146b7, 246, 255, 256, 262,
 264–268, 270, 272, 274
 miR-148a 60, 248
 miR-150 6, 43, 61, 233
 miR-151249, 250

miR-152	59	Mitogen-activated protein kinase (MAPK)	229, 234, 235, 243–245, 251, 254, 265, 270, 276
miR-155	42–44, 46, 59, 61, 245, 255, 262, 266, 270, 271	Multipotent mesenchymal stem cells (MSCs).....	242, 244, 245
miR-181a	60, 249, 250, 252, 255, 262, 266	MYC	5, 162
miR-190b	252	N	
miR-191	61, 233, 263, 269, 271, 272	Network motifs	125–128, 162, 163
miR-192	62, 231, 235, 236, 262, 268, 270	Neurodegenerative diseases	3, 6–7, 11, 13–14, 61, 63
miR-194	62	Next-generation sequencing (NGS).....	63, 78, 117, 120, 169–176, 220
miR-196a	62, 119	Non-coding RNAs	1, 4, 27, 31, 35, 51, 226
miR-197	61, 119, 233, 249, 250, 262, 268, 270	Non-supervised method	183–185
miR-199	62	Normalization	189–190, 192, 194, 195
miR-199a-3p.....	60, 232, 266	O	
miR-199a-5p.....	61, 119, 263	Obesity	75, 230, 233, 249, 255, 256
miR-200 family	273, 275	Oncogenes.....	4, 5, 11, 15, 33, 44, 59, 62, 251, 265
miR-200a	5, 59, 60	Ontology	85, 86, 89, 208, 214, 216, 217, 221
miR-200c	59, 61	Ovarian cancer.....	58, 194
miR-201	250	P	
miR-203	59, 119, 265, 267	p53.....	12, 45, 162, 228, 273, 275
miR-204	119, 246	Pancreatic cancer	58, 59
miR-205	249, 250	Papillary thyroid carcinomas (PTCs)	58, 261–269, 271–273, 276
miR-208a	61, 232, 254, 255	Parallel analysis of RNA ends (PARE).....	102
miR-210	60, 62, 246, 263	Parkinson's disease	6, 13, 14, 61
miR-211	243	PAX8	270, 273
miR-221	45, 59, 232, 248–251, 262–264, 266–268, 270, 271, 274–276	Peripheral blood mononuclear cells (PBMCs)	255
miR-223	43, 45, 48, 61, 62, 232, 233, 235	Peroxisome proliferator-activated receptor- γ (PPAR γ)	45, 243–246, 248, 249, 270
miR-224	247, 262, 266, 267, 271, 274, 276, 277	Phosphatidylinositol 3-kinase (PI3-K).....	234, 251, 252, 266, 267
miR-278	230, 235, 247	Phosphoribosylanthranilate isomerase (PAI-1).....	243, 244, 246
miR-298	119, 249, 250	Photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP)	101
miR-320	3, 233, 251, 252	PI3K/AKT pathway.....	251
miR-323-3p.....	61	Plasma	5, 57, 59, 62, 63, 228, 229, 233, 247, 250, 254, 255
miR-325	249, 250	Poorly differentiated thyroid carcinomas (PDTCs).....	261
miR-326	243, 245	PRC2.....	9, 11–13
miR-328	61, 249, 250, 262, 270	Precursor miRNA (pre-miRNA).....	2, 28, 30, 34, 99, 127, 212, 213, 215
miR-329	250	Preinitiation complex (PIC)	160
miR-330	249, 250	Primary miRNA (pri-miRNA)	2, 28, 34, 159, 211
miR-335	59, 248, 249	Principal component analysis (PCA).....	184, 185
miR-362-3p.....	61	PRKCQ.....	266
miR-372	59	Prognostics	58, 61, 262, 277
miR-373	3, 59, 119, 232, 235	Promoter.....	3, 5, 9, 11, 33, 51, 124–125, 127, 129, 130, 162, 165, 231
miR-375	119, 226, 227, 234, 245, 262, 270, 276	Prostate cancer.....	12, 58, 59
miR-380-5p.....	249, 250	Protein tyrosine phosphatase 1B (PTP1B).....	251, 252
miR-448	44, 246	Pyruvate kinase M2 (PKM2)	251, 252
miR-502	62		
miR-519d	250		
miR-520c	59		
miR-532-3p.....	61		
miR-802	251, 252		
miRBase	2, 27, 44, 109, 134, 139, 153, 165, 175, 212		
miRNA*	2		
miRNA-16-1.....	59		
miRNA-122	34, 233		
miRNA-433	61		
miRNA replacement	62		
miRNA sponge.....	6, 99		

Q

Quantitative real-time polymerase chain reaction (QRT-PCR)245, 250–252, 267, 271, 274

R

Regulation 5, 9–12, 14, 15, 27–32, 44, 47–49, 52, 58, 61, 93, 94, 98–100, 102, 110, 115, 117, 118, 123–130, 134, 163, 166, 179, 218, 220, 228, 232, 242, 246–248, 250, 254, 256, 266–268, 276

Regulatory interactions..... 125, 130

Regulatory network modules.....219

Regulatory networks.....13, 27, 28, 30, 46, 126, 127, 130, 163, 165, 256

Resources..... 83–86, 120, 180

Reverse transcription qualitative PCR (RT-qPCR) 169, 264–272

Rheumatoid arthritis61

RNA editing..... 32, 34, 47, 118

RNA immunoprecipitation (RIP)100–102

RNA-induced initiation of transcriptional silencing (RITS).....31–32

RNA-induced silencing complex (RISC)..... 2, 3, 6, 28–31, 51, 98, 102, 116, 117, 120, 212

RNA Pol II..... 160, 161

RNA Pol III160

RNA-seq47, 98, 100, 101, 165, 174

RS2 (insulin receptor substrate 2).....251

S

Saliva 57, 59, 63

Semantic web78, 83–85, 87–90, 208, 209

Serum 5, 14, 52, 59, 60, 62, 63, 232, 233, 254, 262, 265

Serum response factor (SRF)..... 14, 232, 235

Single-nucleotide polymorphism (SNPs)..... 5, 32–34, 130, 170, 175, 264

Sirtuin1 (SIRT1)..... 244, 246

Sliced inverse regression (SIR) 183, 185

Smad-interacting protein 1 (SIP1).....231, 235

Small interfering RNAs (siRNAs) 13, 31–32, 51, 99

Small RNAs (sRNAs) 1, 35, 48, 49, 52, 125, 175

SOLiD 170, 171, 173, 174

Splicing.....3, 9–11, 28, 118, 160

STEMI (acute ST-segment elevation MI).....255

Sterol regulatory element-binding proteins (SREBPs) 229, 230, 251, 253

Supervised method.....183–184

Synergistic124, 126, 129–130, 272

T

TARBP2.....30, 59

Target prediction..... 96, 97, 110–117, 120, 134, 135, 140, 142–144, 146–148, 150–152, 154, 156, 215–222

TargetScan..... 3, 95, 97, 112, 113, 119, 128, 136, 144, 155, 156, 208, 216

TF-miRNA network..... 128–129, 163

TGF- β pathway.....266

Therapeutic approach.....273

Therapeutics 12, 45, 52, 57, 77, 226, 233–236, 241, 242, 247, 250, 252, 253, 262, 266, 267, 273

Thyroid cancer 261–264, 271–277

TIMP3 and ZNFR3 gene.....266

Tissue-specific9, 58, 99, 217, 226

3T3-L1 cells 245, 246, 253

Transcription factor (TF)6, 14, 33, 35, 124–130, 160–163, 165, 226–230, 242–246, 263, 273

Transcription factor 7-like 2 (TCF7L2)..... 244, 246

Transcriptional start sites (TSS)..... 124, 125, 160

Transcriptome 98–100, 165

Transforming growth factor- β (TGF- β) 45, 231, 235, 244, 245

Transforming growth factor beta receptor II (TGF β R2)245

Translation..... 2, 3, 6, 10, 14, 27–31, 35, 44, 48, 49, 57, 99, 100, 125, 126, 211, 226, 242, 244, 250, 262, 263

Translational repression 27–30, 35, 49, 99, 117, 159, 231

Translation repression.....57

Triacylglycerol230, 235

TTF1/NKX2-1.....273

Tumor suppressor 4–6, 11, 13, 15, 33, 44, 45, 59, 62, 266, 272, 273

Type 1 diabetes (T1D) 59, 60, 225, 226

Type 2 diabetes (T2D)60, 75, 225, 226, 229, 230, 232, 254

U

Undifferentiated thyroid carcinomas (UDTCs)261

Urine 5, 57–59, 63

Urothelial bladder cancer.....59

V

v-ets Erythroblastosis virus E26 oncogene homologue 1 (ETS1).....251

Viral diseases40–44

Viral infections40, 44, 46, 60, 63

Viral microRNAs39–52

Viral microRNAs cancer relevance.....128

Viral noncoding RNA35

Vitavene62

W

Well-differentiated thyroid carcinomas (WDTCs)..... 261, 268, 275

Wnt/ β -catenin.....266, 267

Z

ZEB1 and ZEB2 protein 42, 231, 273